A phase II study of EC17 (folate-hapten conjugate) in patients with progressive metastatic renal cell carcinoma.

Trial Profile

A phase II study of EC17 (folate-hapten conjugate) in patients with progressive metastatic renal cell carcinoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2012

At a glance

  • Drugs Folate-fluorescein isothiocyanate conjugate; GPI 0100; Interferon alpha; Interleukin-2; Keyhole limpet haemocyanin-fluorescein isothiocyanate conjugate
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Sponsors Endocyte
  • Most Recent Events

    • 11 Feb 2009 Actual patient numbers (12) added as reported by ClinicalTrials.gov.
    • 11 Feb 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 11 Feb 2009 Planned end date changed from 1 Jul 2010 to 1 Mar 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top